- Home
- IFRX vs PDEX Comparison
IFRX vs PDEX Comparison
Compare IFRX & PDEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- PDEX
- Stock Information
- Founded
- IFRX 2007
- PDEX 1978
- Country
- IFRX Germany
- PDEX United States
- Employees
- IFRX N/A
- PDEX N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- PDEX Medical/Dental Instruments
- Sector
- IFRX Health Care
- PDEX Health Care
- Exchange
- IFRX Nasdaq
- PDEX Nasdaq
- Market Cap
- IFRX 117.8M
- PDEX 117.9M
- IPO Year
- IFRX 2017
- PDEX N/A
- Fundamental
- Price
- IFRX $1.05
- PDEX $51.40
- Analyst Decision
- IFRX Strong Buy
- PDEX Strong Buy
- Analyst Count
- IFRX 2
- PDEX 1
- Target Price
- IFRX $9.00
- PDEX $52.00
- AVG Volume (30 Days)
- IFRX 356.5K
- PDEX 41.3K
- Earning Date
- IFRX 03-20-2025
- PDEX 05-01-2025
- Dividend Yield
- IFRX N/A
- PDEX N/A
- EPS Growth
- IFRX N/A
- PDEX 128.87
- EPS
- IFRX N/A
- PDEX 1.93
- Revenue
- IFRX $171,642.00
- PDEX $61,004,000.00
- Revenue This Year
- IFRX $381.73
- PDEX $28.63
- Revenue Next Year
- IFRX $2,277.23
- PDEX $3.09
- P/E Ratio
- IFRX N/A
- PDEX $26.58
- Revenue Growth
- IFRX 162.79
- PDEX 26.45
- 52 Week Low
- IFRX $1.01
- PDEX $16.84
- 52 Week High
- IFRX $2.82
- PDEX $59.60
- Technical
- Relative Strength Index (RSI)
- IFRX 31.57
- PDEX 67.45
- Support Level
- IFRX $1.16
- PDEX $47.00
- Resistance Level
- IFRX $1.30
- PDEX $52.00
- Average True Range (ATR)
- IFRX 0.12
- PDEX 2.56
- MACD
- IFRX 0.02
- PDEX 0.05
- Stochastic Oscillator
- IFRX 9.76
- PDEX 91.84
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.